selected scholarly activity
-
chapters
- 12 Diseases of the Nipple. 154-166. 2011
- 21 Familial Breast Cancer. 279-286. 2011
- Diseases of the Nipple. 154-166. 2011
- Familial Breast Cancer. 279-286. 2011
- Benign Stromal Lesions of the Breast. 125-137. 2006
- Chapter 11 Benign Stromal Lesions of the Breast. 125-137. 2006
- Chapter 12 Diseases of the Nipple. 139-148. 2006
- Chapter 21 Familial Breast Cancer. 241-248. 2006
- Diseases of the Nipple. 139-148. 2006
- Familial Breast Cancer. 241-248. 2006
-
conferences
- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).. Journal of Clinical Oncology. 2022
- Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study. Cancer Research. 2020
- Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology. 225-235. 2019
- Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).. Journal of Clinical Oncology. TPS602-TPS602. 2019
- Mammary Adenoid Cystic Carcinoma - a Multi-Institutional Canadian Study. Laboratory Investigation. 2019
- Mammary Adenoid Cystic Carcinoma - a Multi-Institutional Canadian Study. Modern Pathology. 2019
- Using control charts to assess the consistency of breast cancer grading in 1,453 resections. Virchows Archiv. S199-S199. 2018
- Clinical Significance of the AJCC 8th Edition Prognostic Staging System for Triple Negative Breast Cancer (TNBC). Modern Pathology. 51-52. 2018
- Clinical Significance of the AJCC 8th Edition Prognostic Staging System for Triple Negative Breast Cancer (TNBC). Laboratory Investigation. 51-52. 2018
- Abstract P1-03-01: An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer. Cancer Research. 2017
- Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. npj Breast Cancer. 16014. 2016
- Abstract 4346: Prognostic gene signature for intermediate risk prostate cancer. Cancer Research. 4346-4346. 2015
- Abstract 5289: The role of the immune system in lymph node positive ER+ breast cancer. Cancer Research. 5289-5289. 2015
- Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC). Journal of Clinical Oncology. 2015
- Prognostic potential of thyroid receptor TRα2 in breast cancer.. Journal of Clinical Oncology. e11535-e11535. 2014
- Clinical-Pathologic Significance of Androgen Receptor (AR) Expression in Hormone Receptor (HR) Negative Breast Cancer. Modern Pathology. 48A-48A. 2014
- Clinical-Pathologic Significance of Androgen Receptor (AR) Expression in Hormone Receptor (HR) Negative Breast Cancer. Laboratory Investigation. 48A-48A. 2014
- Abstract A022: The use of LN status on developing prognostic gene signatures for ER+ breast cancer. Molecular Cancer Research. A022-A022. 2013
- Abstract A124: Characterization of claudin-low breast cancers. Molecular Cancer Research. A124-A124. 2013
- Analytical Variables That Affect the Prognostic Utility of Ki67 in Invasive Breast Cancer. Modern Pathology. 74A-75A. 2013
- Analytical Variables That Affect the Prognostic Utility of Ki67 in Invasive Breast Cancer. Laboratory Investigation. 74A-75A. 2013
- Ki 67 in Breast Cancer: How Many Tumor Cells Do We Need To Count?. Laboratory Investigation. 39A-39A. 2013
- Ki 67 in Breast Cancer: How Many Tumor Cells Do We Need To Count?. Modern Pathology. 39A-39A. 2013
- Ki67 in Breast Cancer: The Effect of Different Length of Fixation on Ki 67 Index. Laboratory Investigation. 40A-40A. 2013
- Ki67 in Breast Cancer:The Effect of Different Length of Fixation on Ki 67 Index. Modern Pathology. 40A-40A. 2013
- Abstract 3663: A gene signature for predicting outcome in patients with basal-like breast cancer. Cancer Research. 3663-3663. 2012
- Chromosome 17 Polysomy and Monosomy as Predictive Markers of Complete Pathological Response (pCR) in Women with Locally Advanced Breast Cancer (LABC). Modern Pathology. 36A-36A. 2012
- Chromosome 17 Polysomy and Monosomy as Predictive Markers of Complete Pathological Response (pCR) in Women with Locally Advanced Breast Cancer (LABC). Laboratory Investigation. 36A-36A. 2012
- Claudin-Low Breast Cancer; a Molecular Subtype Associated with Poor Prognosis. Modern Pathology. 34A-34A. 2012
- Claudin-Low Breast Cancer; a Molecular Subtype Associated with Poor Prognosis. Laboratory Investigation. 34A-34A. 2012
- Morphological Characteristics of HER2 Over-Expressing and Basal-Like Breast Cancers and the Association between Lymphocytic Tumor Infiltrate and Prognosis. Modern Pathology. 25A-25A. 2012
- Morphological Characteristics of HER2 Over-Expressing and Basal-Like Breast Cancers and the Association between Lymphocytic Tumor Infiltrate and Prognosis. Laboratory Investigation. 25A-25A. 2012
- Amplification of the Prolactin Receptor Gene in Mammary Lobular Neoplasia. Cancer Research. 757S-757S. 2009
- Expression of Potential Cancer Stem Cell Markers CD44+/CD24-in the Molecular and Genetic Subgroups of Breast Cancer. Modern Pathology. 29A-29A. 2009
- Expression of Potential Cancer Stem Cell Markers CD44+/CD24-in the Molecular and Genetic Subgroups of Breast Cancer. Laboratory Investigation. 29A-29A. 2009
- Androgen receptor expression in breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Modern Pathology. 47A-48A. 2008
- Androgen receptor expression in breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Laboratory Investigation. 47A-48A. 2008
- BRCA1 and BRCA2-associated breast cancers: Morphological and immunohistochemical differences. Laboratory Investigation. 46A-46A. 2008
- BRCA1 and BRCA2-associated breast cancers: Morphological and immunohistochemical differences. Modern Pathology. 46A-46A. 2008
- Histologic characterization of in-situ carcinoma in BRCA1 and BRCA2 mutation carriers without invasive disease: A population-based study. Laboratory Investigation. 52A-52A. 2008
- Histologic characterization of in-situ carcinoma in BRCA1 and BRCA2 mutation carriers without invasive disease: A population-based study. Modern Pathology. 52A-52A. 2008
- Molecular profiling of BRCA1 and BRCA2-associated breast cancers identifies FGFR2 as a gene differentially expressed in BRCA2-associated breast cancers. Modern Pathology. 22A-22A. 2008
- BRCA2 deficiency and EMSY amplification; Possible mutually exclusive genetic events in the development of breast cancer. Modern Pathology. 24A-24A. 2007
- BRCA2 deficiency and EMSY amplification; Possible mutually exclusive genetic events in the development of breast cancer. Laboratory Investigation. 24A-24A. 2007
- BRCA2 associated breast cancers exhibit a luminal phenotype despite their high histologic grade. Modern Pathology. 21A-21A. 2006
- BRCA2 associated breast cancers exhibit a luminal phenotype despite their high histologic grade. Laboratory Investigation. 21A-21A. 2006
- BRCA2 associated breast cancer: Histopathologic and biomarker profiling. Modern Pathology. 25A-26A. 2005
- BRCA2 associated breast cancer: Histopathologic and biomarker profiling. Laboratory Investigation. 25A-26A. 2005
- Columnar cell lesions and flat epithelial atypia: Incidence and significance in a mammographically screened population. Modern Pathology. 41A-41A. 2005
- Columnar cell lesions and flat epithelial atypia: Incidence and significance in a mammographically screened population. Laboratory Investigation. 41A-41A. 2005
- Invasive lobular carcinoma: To grade or not to grade. Modern Pathology. 23A-23A. 2003
- Invasive lobular carcinoma: To grade or not to grade. Laboratory Investigation. 23A-23A. 2003
- Tissue microarrays: accurate assessment of protein and DNA targets requires 3 cores per tumor sample.. Breast Cancer Research and Treatment. S139-S139. 2003
- Polycystic kidney disease presenting as a unilateral mass mimicking multicystic nephroma.. Modern Pathology. 1P-1P. 2002
- Polycystic kidney disease presenting as a unilateral mass mimicking multicystic nephroma.. Laboratory Investigation. 1P-1P. 2002
- Correlation between serum IgA antiendomysial antibody and the duodenal morphology in Coeliac disease. Laboratory Investigation. 81A-81A. 2001
- Correlation between serum IgA antiendomysial antibody and the duodenal morphology in coeliac disease. Modern Pathology. 81A-81A. 2001
- PRIMARY PREVENTION OF CARDIOVASCULAR-DISEASE - SOCIAL PSYCHOLOGICAL PROGRAM TO REDUCE ONSET OF SMOKING AMONG CHILDREN. Circulation. 113-113. 1977
-
journal articles
- The Significance of Thyroid Hormone Receptors in Breast Cancer: A Hypothesis-Generating Narrative Review. Current Oncology. 31:2364-2375. 2024
- Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial. Histopathology. 83:903-911. 2023
- Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. New England Journal of Medicine. 389:612-619. 2023
- Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. British Journal of Cancer. 128:2283-2294. 2023
- Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force. Current Oncology. 30:3079-3090. 2023
- Abstract P4-02-16: Prognostic and Predictive Capacity of Tumor Infiltrating Lymphocytes in the MA.20 regional radiotherapy trial. Cancer Research. 83. 2023
- Abstract P6-04-02: Ki67 Assessment Protocol: Companion Diagnostic Biomarker for LUMINA Prospective Cohort Study. Cancer Research. 83. 2023
- Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology. 35:1362-1369. 2022
- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).. Journal of Clinical Oncology. 40:LBA501-LBA501. 2022
- Predictors of Outcome in Mammary Adenoid Cystic Carcinoma. American Journal of Surgical Pathology. 44:214-223. 2020
- Downregulation of CYB5D2 is associated with breast cancer progression. Scientific Reports. 9:6624. 2019
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications. 10:1741. 2019
- An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Modern Pathology. 32:59-69. 2019
- The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THRα1) Antagonism. Scientific Reports. 8:16562. 2018
- Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. Breast Cancer Research and Treatment. 171:709-717. 2018
- Abstract 2648: Prognostic significance of thyroid hormone receptor-alpha-2 (THRα2) expression in triple-negative breast cancer: A TCGA study. Cancer Research. 78:2648-2648. 2018
- Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. Cancer Letters. 426:4-13. 2018
- Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum. 2:pky023. 2018
- A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer. Biochimica et Biophysica Acta - Molecular Basis of Disease. 1864:735-745. 2018
- Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. Breast Cancer Research. 19:76. 2017
- Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts. Oncotarget. 8:32101-32116. 2017
- Abstract P4-12-09: The immune response in triple negative breast cancer. Cancer Research. 77:p4-12-09-p4-12-09. 2017
- A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer. 104:65-69. 2017
- Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment. 161:117-134. 2017
- Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. PLoS ONE. 12:e0168669-e0168669. 2017
- Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research. 18:15. 2016
- The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures. BMC Cancer. 16:555. 2016
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology. 29:1155-1164. 2016
- Identification and evaluation of network modules for the prognosis of basal-like breast cancer. Oncotarget. 6:17713-17724. 2015
- Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion. Current Medicinal Chemistry. 22:2360-2374. 2015
- An international study to increase concordance in Ki67 scoring. Modern Pathology. 28:778-786. 2015
- Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation. Rare Tumors. 7:89-91. 2015
- Expression of thyroid hormone receptor alpha (THRα) isoforms in triple negative breast cancer (TNBC).. Journal of Clinical Oncology. 33:e12082-e12082. 2015
- Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications. Breast Cancer Research and Treatment. 149:293-301. 2015
- Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research. 16:3419. 2014
- Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology. 25:992-998. 2014
- Abstract C184: Thyroid hormone receptors: Future targets for breast cancer therapy?.. Molecular Cancer Therapeutics. 12:C184-C184. 2013
- Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Research and Treatment. 140:195-205. 2013
- Ductal CarcinomaIn Situ: What the Pathologist Needs to Know and Why. International Journal of Breast Cancer. 2013:1-7. 2013
- Giant Cell Temporal Arteritis Associated with Overlying Basal Cell Carcinoma: Co-Incidence or Connection?. Rare Tumors. 4:148-149. 2012
- A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer. Scientific Reports. 2:227. 2012
- Amplification of the prolactin receptor gene in mammary lobular neoplasia. Breast Cancer Research and Treatment. 128:31-40. 2011
- EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry. Breast Cancer Research and Treatment. 127:831-839. 2011
- CK8/18 expression, the basal phenotype, and family history in identifying BRCA1‐associated breast cancer in the Ontario site of the Breast Cancer Family Registry. Cancer. 117:1350-1359. 2011
- Erratum to: Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Research and Treatment. 126:269-269. 2011
- Amplification of the Prolactin Receptor Gene in Mammary Lobular Neoplasia.. Cancer Research. 69:4151-4151. 2009
- Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer. Nature Reviews Clinical Oncology. 6:604-607. 2009
- Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Research and Treatment. 117:183-191. 2009
- A role for the TGFβ-Par6 polarity pathway in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 106:14028-14033. 2009
- An update on apocrine lesions of the breast. Histopathology. 52:3-10. 2008
- BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays. American Journal of Surgical Pathology. 31:121-128. 2007
- BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50. Cancer Epidemiology, Biomarkers and Prevention. 15:1863-1870. 2006
- Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Modern Pathology. 19:195-207. 2006
- E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Modern Pathology. 18:741-751. 2005
- Invasive lobular carcinoma: to grade or not to grade. Modern Pathology. 18:621-628. 2005
- Linear IgA Disease Presenting as Desquamative Gingivitis. JAMA Otolaryngology - Head and Neck Surgery. 130:469-469. 2004
- The spectrum of apocrine lesions of the breast (vol 11, pg 1, 2003). Advances in Anatomic Pathology. 11:CP2-CP2. 2004
- The Spectrum of Apocrine Lesions of the Breast. Advances in Anatomic Pathology. 11:1-9. 2004
- Massive perivillous fibrinoid causing recurrent placental failure. BJOG: An International Journal of Obstetrics and Gynaecology. 110:292-295. 2003
- Chronic Myelomonocytic Leukemia Revealed by Uncontrollable Hematuria. Archives of Pathology and Laboratory Medicine. 125:657-659. 2001
- Deterring the Onset of Smoking in Children: Knowledge of Immediate Physiological Effects and Coping with Peer Pressure, Media Pressure, and Parent Modeling1. Journal of Applied Social Psychology. 8:126-135. 1978